{
    "data": [
        {
            "id": "4557954",
            "title": "TopBuild outlines $6.075B revenue midpoint for 2026 as M&A and operational discipline drive outlook",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: TopBuild Corp. (BLD) Q4 2025</p>\n<h3>Management View</h3>\n<ul>\n<li><p>CEO Robert Buck reiterated TopBuild’s “clear, profitable growth strategy and a proven track record of delivering compounded growth and strong shareholder returns.” Buck noted “significant growth opportunities across our $95 billion total addressable market” and highlighted strong free cash flow and disciplined capital deployment, both organically and through M&amp;A. He stated, “In the fourth quarter, weakness in the residential and light commercial end markets persisted. Consumer confidence remains low, interest rates are still elevated, and affordability continues to be an issue, all drivers of muted demand in the current environment.” However, Buck emphasized, “the commercial and industrial end markets remain solid...bidding and backlogs are healthy, and we're well positioned to capitalize.”</p></li>\n<li><p>Buck detailed the completion of seven acquisitions in 2025, including SPI in Q4, which fueled a 13.2% sales rise to $1.49 billion for the quarter. He confirmed that “acquisitions continue to be our top priority for capital allocation,” citing $1.9 billion deployed across the business and the addition of approximately $1.2 billion in annual revenue. Buck also announced the recent acquisition of Johnson Roofing, expanding commercial roofing operations in Texas, Louisiana, and Oklahoma.</p></li>\n<li><p>COO John Achille described ongoing operational excellence initiatives, including inventory management and technology platform integration, stating, “Our field teams are doing a great job managing profitability. As soft demand has persisted, we are responding appropriately and making disciplined pricing and volume decisions at the local level.” He added, “We are making great progress on integrating SPI...and we've identified several cross-selling opportunities we expect to realize over time.” Achille confirmed the SPI IT integration is expected to be completed by the end of Q2 2026.</p></li>\n<li><p>CFO Robert Kuhns reflected on “extraordinary growth” over the past decade and provided detail on Q4 results. Kuhns stated, “Acquisitions contributed 23.0%, as both Progressive and SPI had solid quarters and exceeded our expectations...pricing added 0.7%...volume declined 10.5% driven by ongoing weakness in the residential and light commercial end markets.” He cited $265 million adjusted EBITDA for Q4 and $1.04 billion for the year, and commented on cost controls: “On a same branch basis, SG&amp;A was down $19 million or 20 basis points due to cost reduction actions taken during the year.”</p></li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li><p>Kuhns set 2026 guidance for sales of $5.925 billion to $6.225 billion and adjusted EBITDA of $1.005 billion to $1.155 billion. He stated, “The midpoint of our revenue guidance at $6.075 billion is based on the following key assumptions: Overall, we expect volume and price to each be down low-single digits in 2026. Residential sales...will be down mid-single digits, inclusive of both volume and price. Commercial and industrial...is expected to grow low single digits.” M&amp;A closed in the last 12 months is expected to contribute $800 million to $850 million in revenue.</p></li>\n<li><p>Kuhns added, “The midpoint of our adjusted EBITDA guidance at $1.08 billion assumes the following: an EBITDA decremental of approximately 27% on lower volumes; $55 million of price/cost headwinds; and EBITDA margin on M&amp;A in the mid-teens, inclusive of $15 million of Progressive and SPI synergies that will impact 2026.”</p></li>\n<li><p>Buck commented, “while we expect demand will improve, it's not yet clear what that timing will be and it is too early in the year to bank on a second half recovery. This uncertainty is baked into our guidance.”</p></li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li><p>Kuhns reported Q4 net sales of $1.49 billion, up 13.2% year-over-year. Installation Services sales were $798 million, with M&amp;A contributing 16.3%. Specialty Distribution sales totaled $755 million, up 25.5%, with acquisitions contributing 28.9%. Adjusted gross profit was $416 million, margin of 28%. Adjusted EBITDA margin was 17.9% for Q4. Fourth quarter adjusted earnings were $4.50 per diluted share. Cash was $185 million with total liquidity at $1.1 billion.</p></li>\n<li><p>Kuhns highlighted an increase in interest and other expense to $36 million due to expanded credit facilities and new bonds. Working capital was $959 million or 15.4% of sales. Free cash flow for 2025 was $697 million. The company returned $434 million to shareholders via buybacks.</p></li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li><p>Richard Reid, Wells Fargo: Asked about the guide path for single-family starts and differences between public and private builders. Buck responded that “the regional builders, the private regional builders are keeping very cost competitive...smaller custom builders...seem to definitely be holding their own relative to demand.”</p></li>\n<li><p>Reid also inquired about commercial and industrial backlogs. Buck explained, “typically, lighter commercial does follow residential. But we see some trending there in the right direction, we believe. But again, more optimism on the mechanical and the commercial roofing side.”</p></li>\n<li><p>Michael Rehaut, JPMorgan: Focused on pricing trends and the $55 million price/cost headwind. Kuhns replied, “it probably progressively gets a little worse as the year goes on. But we definitely saw some of that pressure in the fourth quarter.” Rehaut asked about specialty distribution leadership realignment. Achille responded, “just making sure we have the right leadership in place,” incorporating talent from SPI and DI.</p></li>\n<li><p>Susan Maklari, Goldman Sachs: Asked about cross-selling from the SPI integration. Achille indicated it is “connecting our sales teams and our managers,” with plans to add digital resources. Maklari also asked about cost structure flexibility. Kuhns said, “more than 70% of our costs are variable. So we can adjust quickly and make changes where we need to.”</p></li>\n<li><p>Margaret Grady, Jefferies: Inquired about pricing and margin guidance. Kuhns said, “the price cost bucket, it's obviously a mixed bag of products, some with price inflation, some with price pressure and price deflation.” He noted mechanical insulation pricing remains strong, while fiberglass and spray foam face pressure.</p></li>\n<li><p>Kenneth Zener, Seaport Research: Pressed on residential volume declines and regional differences. Kuhns stated, “December slowed significantly on the resi side...commercial business...about half...is light commercial work. That's been slow throughout the year.” Achille added, “Florida...it's a bit optimistic down there...Texas, probably still a little flat to slow.”</p></li>\n<li><p>Michael Dahl, RBC: Asked about pricing pressure in fiberglass. Kuhns responded, “pricing is a local decision in our business...we think we do a really good job of adjusting to local markets...but just given the macro environment, we saw it in the fourth quarter.”</p></li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li><p>Analysts maintained a neutral to slightly cautious tone, with multiple questions centered on pricing pressure, volume trends, and the sustainability of cost reductions. Specific focus was given to the risk of continued headwinds in residential and light commercial segments, as well as M&amp;A integration outcomes.</p></li>\n<li><p>Management’s tone in prepared remarks was confident, emphasizing operational discipline and growth opportunities. During the Q&amp;A, management acknowledged macro uncertainty and persistent headwinds but remained focused on controllable factors. Kuhns stated, “we're focused 100% on driving these synergies and getting the results that we can control.”</p></li>\n<li><p>Compared to the previous quarter, analyst sentiment shifted further toward risk mitigation, while management’s confidence remained steady, with more explicit discussion of cautious guidance and contingency planning.</p></li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li><p>Guidance language shifted from a focus on year-end M&amp;A integration and margin resiliency in Q3 to explicit caution about near-term market recovery in Q4, with 2026 guidance assuming no significant change in end market conditions.</p></li>\n<li><p>Strategic focus moved further towards M&amp;A-driven expansion, operational excellence, and capturing synergies, while reiterating discipline in cost management.</p></li>\n<li><p>Key metrics showed an increase in sales and M&amp;A contribution, but gross margin and EBITDA margin declined quarter-over-quarter, primarily due to mix and price/cost headwinds.</p></li>\n<li><p>Analyst questions in both quarters concentrated on pricing, M&amp;A integration, and residential demand outlook, but Q4 included more probing about regional and product-specific trends.</p></li>\n<li><p>Management’s confidence in operational flexibility and synergy capture remained unchanged, though the tone became more measured regarding residential recovery timing.</p></li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li><p>Management identified persistent softness in residential and light commercial demand, driven by low consumer confidence, elevated interest rates, and affordability issues.</p></li>\n<li><p>Kuhns highlighted ongoing price/cost headwinds of $55 million for 2026, with margin pressure linked to mix and competitive pricing, especially in fiberglass and spray foam.</p></li>\n<li><p>Achille noted supply chain dynamics, with “fiberglass pipe insulation remains on allocation.”</p></li>\n<li><p>Analyst concerns centered on the durability of cost savings, pace of price recovery, and the timing of a residential market rebound.</p></li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>TopBuild’s leadership emphasized its disciplined M&amp;A strategy, operational flexibility, and robust free cash flow as key strengths amid a challenging macro environment. The company’s 2026 guidance reflects cautious assumptions about residential demand, offset by anticipated growth in commercial and industrial segments and significant contributions from recent acquisitions. Management remains focused on synergy realization and cost optimization, confident in its ability to adapt to evolving market conditions and deliver long-term shareholder value.</p>\n<p><a href=\"https://seekingalpha.com/symbol/bld/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557954-topbuild-outlines-6_075b-revenue-midpoint-for-2026-as-m-and-a-and-operational-discipline",
            "pub_date": "2026-02-27 00:50:59",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557956",
            "title": "International Seaways declares combined dividend of $2.15",
            "description": "<html><body><ul>\n<li>International Seaways (INSW) declares combined dividend of <a href=\"https://seekingalpha.com/pr/20414885-international-seaways-reports-fourth-quarter-and-full-year-2025-results\" target=\"_blank\">$2.15/share quarterly dividend</a>.</li>\n<li>Payable March 30; for shareholders of record Mar. 20; ex-div Mar. 20.</li>\n</ul>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557956-international-seaways-declares-combined-dividend-of-215",
            "pub_date": "2026-02-27 00:50:59",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557950",
            "title": "Stella Jones GAAP EPS of C$0.91, revenue of C$727M",
            "description": "<html><body><ul>\n<li>Stella Jones <a href=\"https://seekingalpha.com/pr/20414782-stella-jones-announces-fourth-quarter-and-full-year-2025-results\">press release</a>  (STLJF): Q4  GAAP EPS of C$0.91.</li>\n<li>Revenue of C$727M.</li>\n</ul>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557950-stella-jones-gaap-eps-of-c091-revenue-of-c727m",
            "pub_date": "2026-02-27 00:46:01",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557951",
            "title": "Nordic American Tankers declares $0.17 dividend",
            "description": "<html><body><ul>\n<li>Nordic American Tankers (NAT) declares <a href=\"https://seekingalpha.com/pr/20414879-nordic-american-tankers-ltd-nyse-nat-report-as-per-december-31-2025-full-speed-ahead\" target=\"_blank\">$0.17/share quarterly dividend</a>.</li>\n<li>Payable March 24; for shareholders of record March 10; ex-div March 10.</li>\n<li><a href=\"https://seekingalpha.com/symbol/NAT/dividends?source=news_bullet\">See NAT Dividend Scorecard, Yield Chart, &amp; Dividend Growth.</a></li>\n</ul>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557951-nordic-american-tankers-declares-0_17-dividend",
            "pub_date": "2026-02-27 00:46:01",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557908",
            "title": "uniQure falls after FDA commissioner’s comments on rare disease therapy",
            "description": "<html><body><p data-eci=\"true\">uniQure (<span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/QURE\" title=\"uniQure N.V.\">QURE</a></span></span>) shares fell ~28% on Thursday after FDA Commissioner Marty Makary, in a potential reference to Danish biotech’s gene therapy AMT-130, suggested his agency will not approve drugs that are associated with patient morbidity.</p>\n<p>His comments come at a time when uniQure (<a href=\"https://seekingalpha.com/symbol/QURE\" title=\"uniQure N.V.\">QURE</a>) is seeking FDA accelerated approval for AMT-130, which is designed to treat a rare genetically driven neurodegenerative disorder <a href=\"https://seekingalpha.com/news/4538012-uniqure-gains-as-fda-sets-up-meeting-on-gene-therapy\" rel=\"noopener\" target=\"_blank\">called Huntington’s disease.</a></p>\n<p>During an interview with CNBC on rare-disease drug approvals on Thursday, Makary said, \"I think there has been a bit of an effort to find a boogeyman to account for certain products that were not approved.”</p>\n<p>“For example, there was a product where the researchers drilled a burr hole, literally a hole in people's skulls, to interact inject intrathecally into the ventricle\" as part of a randomized controlled trial.</p>\n<p>AMT-130 is administered directly into patients’ brain tissue through a neurosurgical procedure. “At the end of the randomization period, it's found no benefit, and yet, this is one of the drugs that we were pressured to approve,” Makary added.</p>\n<p>“I have a lot of sympathy for those patients. There's <a href=\"https://x.com/adamfeuerstein/status/2027027966945829196?s=20\" rel=\"noopener\" target=\"_blank\">nothing out</a> there to offer them, but we're not going to go ahead and approve something like that that has morbidity associated with it,” he said.</p>\n<p><span data-preserver-spaces=\"true\">However, Leerink Partners reaffirmed its Outperform rating on uniQure (<a href=\"https://seekingalpha.com/symbol/QURE\" title=\"uniQure N.V.\">QURE</a>), arguing that the drug Makary referred to could be </span><span data-preserver-spaces=\"true\">Regenxbio’s</span><span data-preserver-spaces=\"true\"> (<a href=\"https://seekingalpha.com/symbol/RGNX\" title=\"REGENXBIO Inc.\">RGNX</a>) RGX-121 and not AMT-130.</span></p>\n<p><span data-preserver-spaces=\"true\">A gene therapy targeting rare neurodegenerative diseases known as Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis type I (MPS I), RGX-121, is delivered intrathecally into a ventricle using burr holes, analyst Joseph Schwartz argued. </span></p>\n<p><span data-preserver-spaces=\"true\">He added that it is not the </span><span data-preserver-spaces=\"true\">FDA's</span><span data-preserver-spaces=\"true\"> policy to comment on a drug under its review. Instead,</span><span data-preserver-spaces=\"true\"> “</span><span data-preserver-spaces=\"true\">this suggests this was about a drug that had been officially reviewed and rejected,</span><span data-preserver-spaces=\"true\">” </span><span data-preserver-spaces=\"true\">the analyst wrote, referring to RGX-121, for which the FDA issued a complete response </span><a href=\"https://seekingalpha.com/news/4549257-regenxbio-stock-drops-on-fda-setback-for-rgx-121-gene-therapy\" rel=\"noopener\" target=\"_blank\"><span data-preserver-spaces=\"true\">letter earlier this month</span></a><span data-preserver-spaces=\"true\">.</span></p>\n<p><em><span data-preserver-spaces=\"true\">Update 11.37 AM ET: Adds comments from Leerink Partners</span></em></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557908-uniqure-falls-fda-commissioners-comments",
            "pub_date": "2026-02-27 00:40:50",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557948",
            "title": "Cascades Non-GAAP EPS of $0.40, revenue of $4.77M",
            "description": "<html><body><ul>\n<li>Cascades <a href=\"https://seekingalpha.com/pr/20414789-cascades-reports-results-for-the-fourth-quarter-and-full-year-2025\">press release</a>  (CADNF): Q4  Non-GAAP EPS of C$0.40.</li>\n<li>Revenue of C$4.77M.</li>\n</ul>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557948-cascades-non-gaap-eps-of-0_40-revenue-of-4_77m",
            "pub_date": "2026-02-27 00:40:50",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557945",
            "title": "Akebia outlines 2026 pipeline expansion and expects Vafseo data catalysts in $1B dialysis market",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: Akebia Therapeutics (AKBA) Q4 2025  </p>\n<h3>Management View</h3>\n<ul>\n<li>CEO John Butler emphasized that \"2025 was an important year for Akebia, marked by the commercial launch of Vafseo\" and highlighted total net product revenue of $227 million for the year, with Vafseo and Auryxia as key contributors. Butler noted, \"the body of evidence is growing that supports the potential for Vafseo to become standard of care in what is a $1 billion U.S. market opportunity after the TDAPA period ends when we expect Vafseo will be priced roughly in parity with ESA pricing.\"</li>\n<li>Butler discussed the impact of new clinical data, stating, \"At the ASN meeting in November, we presented a post-hoc hierarchical composite endpoint analysis...patients treated with Vafseo experienced a lower risk of dying or being hospitalized than patients treated with the ESA comparator.\"</li>\n<li>The CEO announced a cost comparison analysis to be presented at the ADC, showing Vafseo \"demonstrated a 7.7% lower annual hospitalization rate, 16% reduction in hospitalization days and...approximately 15% lower Medicare hospitalization costs for patients treated with Vafseo versus darbepoetin.\"</li>\n<li>Butler introduced the company’s rare kidney disease pipeline, noting, \"Strategically, this initiative is a natural extension for us as it leverages our expertise in kidney disease drug development.\" Plans include an R&amp;D Day on April 2 to discuss mid-stage assets such as praliciguat and AKB-097, with a Phase II trial for praliciguat and a Phase II basket trial for AKB-097 expected to initiate in the second half of 2026.</li>\n<li>SVP &amp; Chief Commercial Officer Nicholas Grund reported, \"During the quarter, approximately 800 prescribers wrote a prescription for Vafseo...128 of those were new prescribers.\" Grund highlighted expanding access, improved adherence, and momentum in 2026, with \"first refill adherence with approximately 87% among the now larger subset of patients on an observed dosing regimen.\"</li>\n<li>CFO Erik Ostrowski stated, \"Total revenues were $57.6 million in Q4 '25 compared to $46.5 million in Q4 '24 and $236.2 million in calendar year '25 compared to $160.2 million in calendar year '24. These increases were driven by sales of Vafseo and an increase in Auryxia sales.\"</li>\n<li>Ostrowski also noted, \"Net loss in Q4 '25 decreased to $12.2 million as compared to a net loss of $22.8 million in Q4 '24. Net loss for the year also decreased to $5.3 million in calendar year '25 as compared to a net loss of $69.4 million in calendar year '24.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Management did not provide explicit revenue guidance for 2026, but Butler indicated, \"we're not guiding for revenue...we absolutely expect and are seeing growth from that level. We don't know exactly how quickly that will increase.\"</li>\n<li>Butler described expectations for Vafseo growth as \"steady growth month-over-month, quarter-over-quarter as we start to penetrate deeper in terms of breadth and depth.\"</li>\n<li>The company plans to initiate a Phase II open-label basket trial for AKB-097 in the second half of 2026 and a Phase I study in healthy volunteers of AKB-9090 in the first half of 2026.</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Total revenues for Q4 2025 were $57.6 million, with Vafseo net product revenues at $6.2 million and Auryxia net product revenues at $48.1 million. Net loss in Q4 2025 was $12.2 million. Cash and cash equivalents as of year-end stood at $184.8 million.</li>\n<li>Ostrowski indicated, \"We believe our existing cash resources and cash from operations will be sufficient to fund our current operating plans for at least the next 2 years.\"</li>\n<li>Cost of goods sold was $12.5 million in Q4 2025. R&amp;D expenses rose to $26.6 million, including a $12.8 million charge related to AKB-097 acquisition. SG&amp;A expenses were $26.1 million.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Julian Harrison, BTIG: Asked about expectations for Vafseo growth in 2026 and inventory-adjusted demand. Butler responded, \"we're not guiding for revenue...demand basically has been flat. We had $12 million in the third quarter, $11 million in the fourth quarter...we absolutely expect and are seeing growth from that level.\"</li>\n<li>Harrison also questioned the impact of upcoming VOICE study data. Butler stated, \"as these things are published available and our sales and medical affairs folks can use them, these are the things that influence utilization and physicians.\"</li>\n<li>Unknown Analyst (Jefferies): Inquired about refill rates and anemia manager education. Grund explained, \"We've seen this continuation of this high 80%, 90% adherence rate even through the second prescription.\"</li>\n<li>Unknown Analyst (Leerink Partners): Asked about the VOCAL study endpoints and protocol changes for AKB-097. Burke said, \"The primary endpoint is non-inferiority for hemoglobin control...the red blood cell study will be interesting and important.\"</li>\n<li>Unknown Analyst (Piper Sandler): Queried about the upcoming R&amp;D Day. Butler stated, \"we really want to focus on praliciguat and 097...hearing the excitement around that product from people other than Akebia employees, I think, is important.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts were focused on operational execution, adherence improvements, and clinical data catalysts, with a neutral-to-slightly-positive tone as they sought further clarity but acknowledged progress.</li>\n<li>Management maintained a confident and proactive tone, with Butler saying, \"I've never been more confident that the data that we're generating supports that managing anemia with a HIF-PHI...is going to be standard of care.\"</li>\n<li>Compared to the previous quarter, management’s tone shifted from addressing operational hurdles to emphasizing growth potential and confidence in clinical differentiation and pipeline expansion.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Management’s commentary moved from operational challenges and protocol implementation in Q3 2025 to broader prescriber access and improved adherence in Q4 2025.</li>\n<li>The rare kidney disease pipeline was introduced as a new strategic focus, with multiple mid-stage and early-stage assets detailed for the first time.</li>\n<li>Q4 highlighted a decrease in Vafseo revenue due to inventory drawdown, but stronger cash and decreased net loss were reported.</li>\n<li>Analysts in Q4 focused more on growth prospects, data catalysts, and pipeline differentiation compared to operational issues and initial launch metrics in Q3.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Management cautioned about generic competition for Auryxia, stating, \"expect Auryxia revenues to decrease in 2026 as compared to 2025 Auryxia revenues.\"</li>\n<li>Adherence and operational execution for Vafseo remain under close watch, with ongoing efforts to improve protocols and education.</li>\n<li>No explicit mention of regulatory risks or additional financial uncertainties beyond those discussed.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>Akebia management remains confident in the commercial trajectory of Vafseo and the strategic expansion into rare kidney disease therapies, highlighting improved adherence, expanded prescriber access, and a robust pipeline. With upcoming data from VOCAL and VOICE studies, anticipated protocol-driven growth, and a strong balance sheet, the company is positioned to pursue standard-of-care status for Vafseo in the $1 billion U.S. dialysis market while advancing multiple clinical programs in 2026 and beyond.</p>\n<p><a href=\"https://seekingalpha.com/symbol/akba/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557945-akebia-outlines-2026-pipeline-expansion-and-expects-vafseo-data-catalysts-in-1b-dialysis",
            "pub_date": "2026-02-27 00:31:30",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557936",
            "title": "PayPal drops on report Stripe isn't in talks for a takeover",
            "description": "<html><body><p data-eci=\"true\">PayPal (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/PYPL\" title=\"PayPal Holdings, Inc.\">PYPL</a></span>) fell 2.6% after a report that the company isn't in talks to sell itself to Stripe (Stripe) or anyone else. </p>\n<p>PayPal (<a href=\"https://seekingalpha.com/symbol/PYPL\" title=\"PayPal Holdings, Inc.\">PYPL</a>) has been working for months to prepare for a possible activist campaign or unwanted takeover offer, according to a<a href=\"https://www.semafor.com/article/02/26/2026/paypal-stripe-not-currently-in-talks\" rel=\"nofollow\" target=\"_blank\" title=\" Semafor report \"> Semafor report </a>on Thursday, which cited people familiar with the matter. </p>\n<p>PayPal (<a href=\"https://seekingalpha.com/symbol/PYPL\" title=\"PayPal Holdings, Inc.\">PYPL</a>) declined to comment to Semafor. Stripe didn’t immediately return a request for comment. </p>\n<p>The Semafor item comes after a Bloomberg report on Tuesday that <span>Stripe was<a href=\"https://seekingalpha.com/news/4556161-paypal-jumps-on-report-stripe-is-considering-acquisition\" target=\"_blank\" title=\" considering an acquisition \"> considering an acquisition </a>of all or parts of PayPal (<a href=\"https://seekingalpha.com/symbol/PYPL\" title=\"PayPal Holdings, Inc.\">PYPL</a>). PayPal shares soared 6% on Monday after a Bloomberg report that PayPal<span> had piqued the interest of<a href=\"https://seekingalpha.com/news/4555316-paypal-stock-jumps-after-stock-slump-said-to-spark-suitors-interest#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews\" rel=\"noopener\" target=\"_blank\" title=\" some potential acquirers. \"> some potential acquirers.</a></span></span></p>\n<p> </p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557936-paypal-drops-on-report-stripe-isnt-in-talks-for-a-takeover",
            "pub_date": "2026-02-27 00:31:30",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557942",
            "title": "Hormel expects 1%–4% organic net sales growth in 2026 as it divests whole-bird turkey business and advances protein strategy",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: Hormel Foods Corporation (HRL) Q1 2026</p>\n<h3>Management View</h3>\n<ul>\n<li>Interim CEO Jeffrey Ettinger announced \"organic net sales growth of 2%, which marks our fifth consecutive quarter of organic net sales growth. We also achieved adjusted diluted earnings per share of $0.34.\" Ettinger emphasized the \"strength of our protein-centric portfolio\" and highlighted \"high single-digit organic net sales growth\" in both Foodservice and International segments, noting that this was \"partially offset by the decline in our Retail segment.\"</li>\n<li>Ettinger outlined the \"definitive agreement to sell our whole-bird turkey business to Life-Science Innovations,\" clarifying, \"the sale involves the hen side of our turkey complex\" but \"will not affect our value-added turkey products, and we will continue to own and use the Jennie-O brand name.\" The transaction is expected to close by the end of fiscal Q2 and is designed to \"reduce our exposure to volatile commodity-driven businesses and sharpen our focus on our value-added protein portfolio.\"</li>\n<li>President John Ghingo stated, \"We had an encouraging start to fiscal 2026 with strong performance in both our Foodservice and International segments.\" He pointed to \"strategic exit from select non-core private label snack nuts items\" as a factor in Retail's decline but highlighted that \"priority brands delivered year-over-year dollar sales consumption growth, including Jennie-O ground turkey, Planters snack nuts, Hormel Gatherings party trays, Applegate meats, and Hormel entrées.\"</li>\n<li>Ghingo introduced several leadership changes, including the appointment of Jeff Baker as Group Vice President of Enterprise Business Performance, Natosha Walsh as Group Vice President of Retail Sales, Jason Levine as Enterprise Chief Marketing Officer, and Domenic Borrelli as Executive Vice President of Retail.</li>\n<li>Interim CFO Paul Kuehneman reported, \"Q1 net sales were just over $3 billion, a 2% organic net sales increase compared to the prior year... Adjusted operating income for the first quarter was $247 million, and adjusted operating margin was 8.2%.\" Kuehneman confirmed \"cash flow from operations was $349 million, up $26 million from last quarter.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Kuehneman reaffirmed, \"we are reiterating our adjusted full year fiscal 2026 guidance. We continue to expect organic net sales growth of 1% to 4%... adjusted operating income growth of 4% to 10%, and adjusted diluted earnings per share to be in the range of $1.43 to $1.51 per share.\"</li>\n<li>Ettinger stated, \"For Q2, we expect to deliver another quarter of top line growth and adjusted diluted EPS that is in the range of flat to slightly up compared to last year.\"</li>\n<li>The impact of the pending whole-bird turkey transaction on fiscal 2026 is expected to be a reduction of approximately $50 million to net sales, with the majority of sales remaining part of reported results for the year.</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Kuehneman reported, \"Gross profit continued to be hampered in the first quarter with top line growth more than offset by higher input costs and higher-than-expected logistics expenses.\"</li>\n<li>Adjusted SG&amp;A as a percent of net sales was comparable to the prior year, with \"reduction in marketing and advertising expenses... offset by higher employee-related and legal expenses.\"</li>\n<li>Capital expenditures for the quarter were $69 million, with largest projects in China and continued investments in data and technology.</li>\n<li>Dividends returned approximately $160 million to stockholders, marking the 390th consecutive quarterly dividend.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Thomas Palmer, JPMorgan: Asked for Q2 segment-level expectations and for commentary on logistics headwinds. Ettinger explained, \"we believe we remain on a path to generate the sequential but modest bottom line improvement in Q2... we are carefully watching the more challenging freight cost environment.\"</li>\n<li>Palmer also questioned the rationale for the whole turkey divestiture. Ettinger said, \"it's highly volatile and it's low margin... in a typical year, it is significantly dilutive to retail margins,\" while Ghingo described the move as allowing \"us to increase our focus and accelerate the efforts on that part of the business, in particular, from a Retail perspective or thriving ground turkey business.\"</li>\n<li>Leah Jordan, Goldman Sachs: Sought more detail on the Retail segment and future margin improvement. Ghingo detailed that \"profitability for the quarter, certainly below prior year\" due to commodity costs and logistics, but stated, \"we will continue to get additional benefits from that second wave of pricing action in Q2 and beyond.\"</li>\n<li>Ryan Edward Lavin, Barclays: Asked about Foodservice pricing. Ghingo responded, \"there is a lag time on our Foodservice. The prices will follow the markets... pricing coming back in line with the market movements, which did help us on the margin side.\"</li>\n<li>Heather Jones, Heather Jones Research: Queried the volume decline in Retail. Ghingo attributed it to \"the exit of that private label snack nuts business,\" \"volume softness on a couple of businesses, including SKIPPY,\" and \"elasticities related to pricing.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts focused on segment-level expectations, margin improvement, and the strategic rationale behind the whole-bird turkey sale, often pressing for details about headwinds and profit recovery, exhibiting a neutral to slightly skeptical tone.</li>\n<li>Management maintained a confident tone in prepared remarks, highlighting \"conviction as we look ahead\" and \"confidence in the plan we are executing,\" but became more cautious when discussing logistics costs and Retail profitability, using language such as \"carefully watching\" and \"committed to executing with urgency and precision.\"</li>\n<li>Compared to the previous quarter, management's tone shifted from addressing disappointment and missed earnings goals to signaling a more optimistic stance based on early 2026 results.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Guidance for fiscal 2026 was reiterated, with organic net sales growth of 1% to 4% and adjusted diluted EPS of $1.43 to $1.51 per share, unchanged from Q4 2025.</li>\n<li>The strategic focus sharpened with the announcement of the whole-bird turkey divestiture, compared with continued portfolio reshaping and transformation initiatives discussed previously.</li>\n<li>Analyst questions this quarter centered more on the operational impacts and rationale behind strategic divestitures, as well as logistics and margin recovery, while the previous quarter featured more inquiries about cost assumptions and portfolio review.</li>\n<li>Management appeared more confident in growth levers and strategic direction, compared to the defensive posture adopted in Q4 2025 following a disappointing fiscal year.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Management flagged higher input costs—especially beef, pork trim, and nuts—as ongoing headwinds, noting \"beef remained a significant inflationary pressure\" and \"pork trim increased 12% compared to last year.\"</li>\n<li>Unexpected increases in logistics and transportation expenses in Q1 were highlighted as an emerging concern, with monitoring underway for persistence.</li>\n<li>The divestiture of the whole-bird turkey business is expected to reduce sales by approximately $50 million in fiscal 2026, with a larger impact in 2027.</li>\n<li>Analysts questioned the ability to achieve margin improvement in Retail and the sustainability of profit recovery given commodity and logistics pressures.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>Management emphasized that Hormel Foods began fiscal 2026 with momentum in both Foodservice and International segments, supported by its protein-centric strategy and a more focused brand portfolio. The company reaffirmed its full-year guidance for organic net sales and earnings, citing benefits from pricing actions, operational improvements, and the upcoming divestiture of the volatile whole-bird turkey business. While input and logistics costs remain challenges, leadership changes and targeted investments are positioned as key drivers for long-term growth and margin expansion.</p>\n<p><a href=\"https://seekingalpha.com/symbol/hrl/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557942-hormel-expects-1-percent-4-percent-organic-net-sales-growth-in-2026-as-it-divests-whole-bird",
            "pub_date": "2026-02-27 00:20:47",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4557941",
            "title": "NovoCure outlines $675M–$705M 2026 revenue target as new indications fuel growth",
            "description": "<html><body><p data-eci=\"true\">Earnings Call Insights: NovoCure Limited (NVCR) Q4 2025  </p>\n<h3>Management View</h3>\n<ul>\n<li>Executive Chairman William Doyle highlighted that \"2025 was a year of progress and change at NovoCure. We generated a record $655 million in net revenues last year, an 8% increase from 2024.\" Doyle pointed to final data presentations from two large randomized trials, FDA PMA submissions for TTFields therapy in pancreatic cancer and brain metastases, and the rollout of product enhancements for TTFields therapy. </li>\n<li>Doyle announced the first milestone of 2026 was the FDA approval of Optune Pax for locally advanced pancreatic cancer, with regulatory filings submitted in Europe and Japan. He further stated, \"We expect Optune Pax to be a significant contributor to our long-term growth and are eager to begin treating patients in the coming weeks.\"</li>\n<li>Doyle provided a management update: \"Dr. Nicolas Leupin, our Chief Medical Officer, resigned from the company effective February 25...Dr. Uri Weinberg, our Chief Innovation Officer, will now also assume the role of Chief Medical Officer.\" </li>\n<li>CEO Frank Leonard reported, \"2025 was our most successful commercial year to date,\" citing substantial active patient growth across major markets: \"10% year-over-year growth in Germany, 19% in France, and 29% in Japan.\" He noted U.S. active patient growth was 4% after being flat in recent years. Leonard also described plans for a \"tailwind from new market launches in Spain, Czechia, and British Columbia,\" with expectations for modest first-year revenue contributions.</li>\n<li>Leonard explained the Optune Lua launch in Japan is proceeding, and that the company has \"rightsized our marketing spend based on the current demand and are prioritizing investments in indications with a higher return potential, such as pancreatic cancer.\" He emphasized the rapid FDA review and approval of Optune Pax, stating, \"the FDA review was completed exactly at the 180-day mark, with approval received on February 11.\"</li>\n<li>CFO Christoph Brackmann stated, \"Fourth quarter net revenue was $174 million, and full year net revenue totaled $655 million, representing 8% year-over-year growth for both periods.\" Brackmann reported, \"We recognized $3.5 million from Optune Lua claims in the quarter, including $2.4 million from non-small cell lung cancer.\" He addressed a recent Medicare billing issue, saying, \"we do not expect any negative impact on revenue recognition from this matter.\"</li>\n<li>Brackmann provided 2026 guidance: \"annual net revenue guidance at constant exchange rates of $675 million to $705 million, representing year-over-year growth between 3% and 8%.\" He also noted, \"we have decided not to go beyond the $200 million already drawn from our current credit facility.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Management issued guidance of $675 million to $705 million in net revenue for 2026, assuming Optune Gio net revenue growth in the low to mid-single digits and $15 million to $25 million in net revenue contributions from non-GBM products. Brackmann stated, \"For 2026, we expect gross margin in the mid-70s percentage range.\"</li>\n<li>Adjusted EBITDA guidance for 2026 was set at negative $20 million to breakeven for the full year. Leonard emphasized, \"we want to drive to adjusted EBITDA breakeven as a possibility this year.\"</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Fourth quarter net revenue was $174 million, with full year net revenue of $655 million, both up 8% year-over-year. Gross margin was 76% for the quarter and 75% for the full year, compared to 79% and 77% in the respective 2024 periods. </li>\n<li>R&amp;D costs in the quarter were $61 million, up 19% year-over-year, and $225 million for the full year. Sales and marketing expenses were $69 million for Q4 and $240 million for the year. G&amp;A expenses for Q4 were $43 million, down 41% year-over-year; full year G&amp;A was $178 million, down 6%. </li>\n<li>Net loss for Q4 was $24 million, loss per share was $0.22; full-year net loss was $136 million or $1.22 per share. Adjusted EBITDA was negative $16 million for Q4 and negative $34 million for the full year. Cash and investments ended at $448 million after repayment of $561 million in convertible notes.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Jason Bednar, Piper Sandler: Asked about the rationale for providing guidance and details behind revenue assumptions, including new international markets and denied claims. Leonard explained, \"one of the core messages that we've heard is that we need to speak more clearly in terms of setting expectations of what we can accomplish in the coming year.\" Brackmann added, \"there's our GBM business in established markets...GBM in newer markets...and then the third bucket of growth would be new indications...expecting contributions in the range of $15 million to $25 million.\"</li>\n<li>Kevin Joaquin, Evercore ISI: Inquired if guidance for Optune Gio reflected market conservatism. Leonard responded, \"we are not seeing -- we're not signaling a conservatism or a moderation. We're trying to signal that...there are still many patients who will benefit from Optune Gio.\"</li>\n<li>Larry Biegelsen, Wells Fargo: Asked how Optune Pax will be prescribed and lessons learned from lung launch. Leonard highlighted, \"Optune Pax is being approved for locally advanced pancreatic cancer in a first-line setting...a highly motivated patient population.\"</li>\n<li>Albert Aginis, Leerink Partners: Asked about sales force allocation for Optune Pax. Doyle answered, \"we have an established team that we've trained over the last 2 years...we are simply leveraging the team that we have.\"</li>\n<li>Emily Bodnar, H.C. Wainwright: Requested details on revenue contribution for Optune Pax and sales force coverage. Leonard explained, \"as we launch in a new indication, we do...need to go through a process of working with the payers to establish coverage policies,\" and Brackmann noted, \"we expect it will take us about 1 to 2 years to get coverage on a more routine basis for commercial payers.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts largely focused on clarity of guidance, revenue contributions from new markets, and execution around new product launches, with a neutral to slightly positive tone as reflected in congratulatory remarks and requests for detail.</li>\n<li>Management response was confident and direct, with Leonard stating, \"we want to send the signal first at the top line that we are committed to returning the company to steady growth,\" while Brackmann outlined specifics around guidance and expense management. </li>\n<li>Compared to the previous quarter, the sentiment moved from cautious optimism about new launches to a more assertive and confident stance on guidance, profitability timelines, and operational execution.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Management shifted from emphasizing the challenges and learning curve of new launches (notably in lung cancer) to highlighting a record year, a catalyst-rich 2026, and the issuance of annual revenue and profitability guidance for the first time.</li>\n<li>Strategic focus evolved from building infrastructure for multi-indication launches to leveraging existing teams and platforms for new product rollouts.</li>\n<li>Analysts’ questions shifted from launch execution details and ramp expectations to specifics on revenue guidance, market assumptions, and profitability.</li>\n<li>Key metrics improved, with net revenue and active patient counts reaching record highs, and management now targeting breakeven adjusted EBITDA as early as 2026, compared to a previous target of 2027.</li>\n<li>Management confidence increased, with explicit statements about readiness to guide and a clear path to profitability.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Doyle addressed a management change, noting the resignation of Chief Medical Officer Dr. Nicolas Leupin and the appointment of Dr. Uri Weinberg to the combined CMO/Chief Innovation Officer role.</li>\n<li>Brackmann discussed a recent Medicare billing suspension, noting that billing privileges were reinstated retroactively and that \"we do not expect any negative impact on revenue recognition from this matter.\"</li>\n<li>Leonard cautioned that in new indication launches, \"there will be a lag as we establish the coverage policies and the payment policies with payers in the United States,\" suggesting a delay in revenue recognition for Optune Pax.</li>\n<li>Brackmann noted that some launch costs and gross margin pressures are expected as new indications come online and coverage is established.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>NovoCure’s 2025 performance marked a year of record net revenue and active patient growth, underpinned by expansion in key markets and regulatory milestones including the FDA approval of Optune Pax for pancreatic cancer. The company signaled a clear path toward profitability with 2026 guidance of $675 million to $705 million in net revenue and a target of breakeven adjusted EBITDA, leveraging existing sales infrastructure for new product launches and focusing on operational discipline. Management changes and recent Medicare billing challenges were addressed transparently, with no expected negative impact on revenue. The upcoming year is described as catalyst-rich, with expectations for further regulatory, clinical, and commercial milestones to drive long-term growth.</p>\n<p><a href=\"https://seekingalpha.com/symbol/nvcr/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n<div class=\"signup_widget_placeholder\"></div>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4557941-novocure-outlines-675m-705m-2026-revenue-target-as-new-indications-fuel-growth",
            "pub_date": "2026-02-27 00:20:47",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        }
    ]
}